 |
|
|
|
 |
|
|
| Article 1 to 8 out of 8 concerning Medicago, Inc.
|
-
Medicago to evaluate establishment of a pandemic vaccine production facility in France in collaboration with Genopole d'Evry
(17 Jul 2008)
Medicago Inc. announced that it will conduct a feasibility study in collaboration with Genopole biopark, in Evry, for the establishment of a vaccine production facility in France. Medicago has obtained a grant from the Quebec Ministry of Economic ...
-
Medicago's H5N1 pandemic flu vaccine effective in key ferret animal model with single dose
(06 Jun 2008)
Medicago Inc. announced positive results from a preclinical immunogenicity study of the Company's H5N1 Avian Influenza VLP vaccine that was performed in ferrets, the most predictive animal model for the effectiveness of influenza vaccines in humans. ...
-
Medicago completes cGMP qualification of its manufacturing facility
(22 Apr 2008)
Medicago Inc. announced that it has successfully completed the current Good Manufacturing Practices ("cGMP") qualification of its manufacturing facility located in the Technology Park of Québec City, Canada. cGMP rules and regulations governing the ...
-
Medicago's H5N1 VLP vaccine provides protection against multiple strains of avian flu
(25 Mar 2008)
Cross-protection established against deadly Vietnam strain
Medicago Inc. announced that its H5N1 Avian Influenza VLP vaccine, made from the Indonesian strain, provided 100% protection in mice against a lethal challenge with live H5N1 viruses of the Vietnam strain. Including these results, the Company has ...
-
Medicago's Pandemic Flu Vaccine Provides 100% Protection in Mice at Low Doses
(24 Jan 2008)
Medicago Inc. announced that low doses of the Company's H5N1 Avian Influenza VLP vaccine ("H5N1 VLP vaccine") provided 100% protection in mice against a lethal challenge of live H5N1 viruses. In addition, this preclinical study demonstrated that ...
-
Medicago and PBL sign license agreements for PBL's bipartite expression and related technologies
(10 Aug 2006)
Medicago and PBL (Plant Bioscience Limited) announced the signing of license agreements to give Medicago access to a range of technologies for the high level expression of heterologous proteins in plants. The agreements give Medicago access to PBL's ...
-
Medicago and InterveXion Therapeutics Establish Alliance to Develop Antibody Therapeutics
(09 Jun 2005)
Medicago and InterveXion Therapeutics, announced the formation of multi-year product co-development collaboration. The two companies will use Medicago's Proficia(TM) Protein Technology for the production of monoclonal antibodies therapeutics ...
-
Medicago announces research collaboration with Bayer CropScience
(04 Feb 2005)
Medicago, Inc. announced that it has entered into a product development agreement with Bayer CropScience L.P. in the field of Plant-Made Pharmaceuticals. The goal of the collaboration is to assess the feasibility of using Medicago's proprietary ...
Additional information
Medicago, Inc.
Québec, Canada
Company
|
|
|
|
|
|
Top
